Bill Jehling was diagnosed with acute myeloid leukemia (AML) at age 51 and was given just a 40 percent chance of survival. He took his diagnosis in stride, tried to remain positive and sought cancer care at Siteman Cancer Center.
Siteman, widely recognized as a premier leukemia program in the country, is one of only two institutions to receive a Specialized Program of Research Excellence (SPORE) grant in leukemia from the National Cancer Institute.
In this video, Daniel Link, MD, shares how this promising research could lead to new treatments for patients like Bill, and how donors to The Foundation to Barnes-Jewish Hospital can make a difference at the Illumination Gala.